Monopar Therapeutics (MNPR) Equity Average (2018 - 2020)
Historic Equity Average for Monopar Therapeutics (MNPR) over the last 3 years, with Q3 2020 value amounting to $14.8 million.
- Monopar Therapeutics' Equity Average rose 20400.75% to $14.8 million in Q3 2020 from the same period last year, while for Sep 2020 it was $14.8 million, marking a year-over-year increase of 20400.75%. This contributed to the annual value of $9.8 million for FY2019, which is 1819.14% up from last year.
- Per Monopar Therapeutics' latest filing, its Equity Average stood at $14.8 million for Q3 2020, which was up 20400.75% from $12.3 million recorded in Q2 2020.
- Monopar Therapeutics' 5-year Equity Average high stood at $14.8 million for Q3 2020, and its period low was $4.9 million during Q3 2019.
- Moreover, its 3-year median value for Equity Average was $8.5 million (2018), whereas its average is $8.9 million.
- In the last 5 years, Monopar Therapeutics' Equity Average tumbled by 3788.49% in 2019 and then soared by 20400.75% in 2020.
- Quarter analysis of 3 years shows Monopar Therapeutics' Equity Average stood at $7.2 million in 2018, then grew by 19.03% to $8.6 million in 2019, then surged by 71.83% to $14.8 million in 2020.
- Its last three reported values are $14.8 million in Q3 2020, $12.3 million for Q2 2020, and $12.5 million during Q1 2020.